Non-steroidal anti-inflammatory drug use and the risk of benign prostatic hyperplasia-related outcomes and nocturia in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial

BJU International

Volumn 110, Issue 7, 2012, Pages 1050-1059

  Sutcliffe, Siobhan ^a   Grubb Iii, Robert L ^b   Platz, Elizabeth A ^c   Ragard, Lawrence R ^d   Riley, Thomas L ^e   Kazin, Sally S ^g   Hayes, Richard B ^h   Hsing, Ann W ^f   Andriole, Gerald L ^b  

^a WASHINGTON UNIVERSITY   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d Information Management Services ^*  (United States)

^e INFORMATION MANAGEMENT SERVICES INC   (United States)

^f NATIONAL CANCER INSTITUTE   (United States)

^g UNIVERSITY OF GEORGIA   (United States)

^h NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

aspirin; benign prostatic hyperplasia; ibuprofen; lower urinary tract symptoms; non steroidal anti inflammatory drugs

Indexed keywords

ACETYLSALICYLIC ACID; FINASTERIDE; IBUPROFEN; PROSTATE SPECIFIC ANTIGEN; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; ARTICLE; CHRONIC DRUG ADMINISTRATION; CLINICAL EFFECTIVENESS; DIGITAL RECTAL EXAMINATION; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; DRUG USE; FOLLOW UP; HEALTH SURVEY; HUMAN; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; NOCTURIA; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SELF REPORT; TREATMENT OUTCOME; AGED; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; MIDDLE AGED; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; DIGITAL RECTAL EXAMINATION; FOLLOW-UP STUDIES; HUMANS; IBUPROFEN; LOWER URINARY TRACT SYMPTOMS; MALE; MIDDLE AGED; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; RISK FACTORS;

EID: 84871699726     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2011.10867.x     Document Type: Article

References (23)

1. Roehrborn CG, McConnell JD,. Benign prostatic hyperplasia: etiology, pathophysiology, epidemiology, and natural history. In, Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA, eds. Campbell-Walsh Urology, 9th edn. 3. Chapt 86. Philadelphia, PA: Saunders Elsevier, 2007: 2649-73
2. Nickel JC,. Inflammation and benign prostatic hyperplasia. Urol Clin North Am 2008; 35: 109-15
3. Kessler OJ, Keisari Y, Servadio C, Abramovici A,. Role of chronic inflammation in the promotion of prostatic hyperplasia in rats. J Urol 1998; 159: 1049-53
4. Robinette CL,. Sex-hormone-induced inflammation and fibromuscular proliferation in the rat lateral prostate. Prostate 1988; 12: 271-86
5. Odunjo EO, Elebute EA,. Chronic prostatitis in benign prostatic hyperplasia. Br J Urol 1971; 43: 333-7
6. Nickel JC, Downey J, Young I, Boag S,. Asymptomatic inflammation and/or infection in benign prostatic hyperplasia. BJU Int 1999; 84: 976-81
7. Kohnen PW, Drach GW,. Patterns of inflammation in prostatic hyperplasia: a histologic and bacteriologic study. J Urol 1979; 121: 755-60
8. Di Silverio F, Gentile V, De Matteis A, et al,. Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis. Eur Urol 2003; 43: 164-75
9. Mishra VC, Allen DJ, Nicolaou C, et al,. Does intraprostatic inflammation have a role in the pathogenesis and progression of benign prostatic hyperplasia? BJU Int 2007; 100: 327-31
10. Nickel JC, Roehrborn CG, O'Leary MP, Bostwick DG, Somerville MC, Rittmaster RS,. The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur Urol 2008; 54: 1379-84
11. Roehrborn CG,. Definition of at-risk patients: baseline variables. BJU Int 2006; 97 (Suppl. 2): 7-11
12. St Sauver JL, Jacobson DJ, McGree ME, Lieber MM, Jacobsen SJ,. Protective association between nonsteroidal antiinflammatory drug use and measures of benign prostatic hyperplasia. Am J Epidemiol 2006; 164: 760-8
13. Meigs JB, Mohr B, Barry MJ, Collins MM, McKinlay JB,. Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men. J Clin Epidemiol 2001; 54: 935-44
14. Kang D, Andriole GL, Van De Vooren RC, et al,. Risk behaviours and benign prostatic hyperplasia. BJU Int 2004; 93: 1241-5
15. Prorok PC, Andriole GL, Bresalier RS, et al,. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials 2000; 21: 273S-309S
16. Barry MJ, Fowler FJ Jr, O'Leary MP, et al,. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 1992; 148: 1549-57
17. Pinsky PF, Kramer BS, Crawford ED, et al,. Prostate volume and prostate-specific antigen levels in men enrolled in a large screening trial. Urology 2006; 68: 352-6
18. Roehrborn CG, McConnell JD, Lieber M, et al,. Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group. Urology 1999; 53: 473-80
19. Roehrborn CG, McConnell J, Bonilla J, et al,. Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study. J Urol 2000; 163: 13-20
20. Vesely S, Knutson T, Damber JE, Dicuio M, Dahlstrand C,. Relationship between age, prostate volume, prostate-specific antigen, symptom score and uroflowmetry in men with lower urinary tract symptoms. Scand J Urol Nephrol 2003; 37: 322-8
21. Abrams P,. Nocturia: the major problem in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction (LUTS/BPO). Eur Urol Suppl 2005; 3: 8-16
22. Siami P, Roehrborn CG, Barkin J, et al,. Combination therapy with dutasteride and tamsulosin in men with moderate-to-severe benign prostatic hyperplasia and prostate enlargement: the CombAT (Combination of Avodart and Tamsulosin) trial rationale and study design. Contemp Clin Trials 2007; 28: 770-9
23. Spiegelman D, Hertzmark E,. Easy SAS calculations for risk or prevalence ratios and differences. Am J Epidemiol 2005; 162: 199-200